according to the annual report disclosed on March 23, Wuxi Apptec Co.Ltd(603259) , the company achieved an operating revenue of 22.902 billion yuan in 2021, with a year-on-year increase of 38.50%, and realized a net profit attributable to shareholders of listed companies of 5.097 billion yuan, with a year-on-year increase of 72.19%; The basic earnings per share is 1.75 yuan. The company’s profit distribution plan for 2021 is to distribute cash of 5.17 yuan for every 10 shares.
In 2021, Wuxi Apptec Co.Ltd(603259) continued to focus on the synergy of the unique “integrated, end-to-end” crdmo business model, strengthened the business diversion between platforms, continuously improved the company’s capacity utilization, and further revealed the scale effect.
The integrated chemical business segment of the company continues to build an “integrated, end-to-end” crdmo (contract research, development and production) business, with strong order demand. Under the test business, laboratory analysis and test business, clinical cro / SMO business and biology business have achieved strong growth.
The service demand of global customers for Wuxi Apptec Co.Ltd(603259) has maintained strong growth. According to the data, in 2021, the company added more than 1660 new customers and the number of active customers exceeded 5700. While the company continued to expand new customers, the original customers maintained a strong stickiness. The total revenue from the original customers was 21.295 billion yuan, a year-on-year increase of 29%; The revenue from new customers was 1.608 billion yuan.
The company’s chemical business segment continues to accelerate capacity construction, and it is expected that the revenue growth rate of this segment will nearly double year-on-year in 2022, which further verifies the effectiveness of the company’s crdmo business model. Biology business and testing business are expected to continue the growth trend of previous years; Moreover, 2022 will be a turning point in the development of cell and gene therapy ctdmo business. It is expected that the revenue growth of this sector is expected to exceed the growth rate of the industry.
Wuxi Apptec Co.Ltd(603259) released the ESG report on the same day, and the company continuously optimized the ESG management system and improved the management level. In 2021, the quantitative environmental protection objectives were defined for the first time, and corresponding action plans were formulated. The company has been recognized by many international authorities. Morgan Stanley Capital International (MSci) rated Wuxi Apptec Co.Ltd(603259) esg as AA; The company was included in the Dow Jones sustainable development (DJSI) emerging market index for the first time; At the same time, the rating of CDP climate change questionnaire is grade B.
Dr. Li Ge, chairman and CEO of Wuxi Apptec Co.Ltd(603259) said: “2021 is another year of great achievements for Wuxi Apptec Co.Ltd(603259) . Our integrated enabling platform is close to the growing needs of customers and continues to make positive contributions to global pharmaceutical innovation. We believe that the business will achieve stronger growth in 2022.”
Dr. Li Ge concluded: looking forward to the future, we will continue to strengthen capacity-building and scale-up globally, and continue to increase investment in new molecular R & D capabilities. The company plans to invest RMB 9-10 billion in capital expenditure in 2022, increase the layout of new capacity and continue to promote the future development of the company. (Li Lin)
